Minimally-Invasive Non-Surgical Therapy of Peri-Implantitis

Minimally-Invasive Non-Surgical Therapy of Peri-Implantitis: A Multicenter Randomized Controlled Trial (MINST vs NSPT)

This multicenter, single-masked randomized controlled clinical trial evaluates the effectiveness of minimally-invasive non-surgical therapy (MINST) compared with standard non-surgical peri-implant therapy (NSPT) in patients diagnosed with peri-implantitis. The study investigates clinical outcomes, radiographic bone levels, patient-reported outcomes, and treatment time over 12 months.

Peri-implantitis is an inflammatory condition characterized by bleeding on probing, probing depths ≥6 mm, and radiographic bone loss. MINST is a refined, tissue-preserving approach using delicate ultrasonic tips under magnification, while NSPT includes ultrasonic debridement combined with steel curettes and soft-tissue curettage. Both treatments are standard of care.

The study includes 7 visits over 12 months, with clinical measurements, radiographs, plaque sampling, PROMs, and standardized instrumentation protocols.

Inclusion Criteria:

• Age ≥18
• Peri-implantitis diagnosis (PPD >6 mm, BOP+, bone loss ≥3 mm)
• Accessible implant surface without removing suprastructure
• FMPS <30%, FMBS <30-35%

Exclusion Criteria:

• Antibiotics in last 3 months
• Pregnancy/lactation
• Uncontrolled diabetes (HbA1c ≥7)
• Long-term SPIC (>2 years)
• Previous implant therapy <12 months
• Smoking/vaping in last 12 months
• Hopeless implant
• Need for adjunctive antibiotics